The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Clinical observation of pemetrexed combined with cisplatin in treatment of cervical cancer
Author(s): 
Pages: 188-191
Year: Issue:  2
Journal: World Phytomedicines

Keyword:  Pemetrexed Disodium for injectionCisplatin for injectioncervical cancer;
Abstract: Objective To investigate the efficacy and safety of pemetrexed combined with cisplatin in treatment of cervical cancer. Methods Patients(100 cases) with cervical cancer who came to Liaoning Cancer Hospital from February 2010 to February 2014 were randomly divided into the control and treatment groups, and each group had 50 cases. The patients in the control group were iv administered with Cisplatin for injection(50 mg/m2 diluted with 250 m L physiological saline) more than 2 h on the first day. The patients in the treatment group were iv administered with Pemetrexed Disodium for injection(500 mg/m2 diluted with 250 m L physiological saline) more than 10 min. And they were given Cisplatin for injection when pemetrexed dripped 30 min later, while the usage and dosage of Cisplatin for injection were same with control group. One course of treatment was 21 D, and two groups were treated for at least four courses of chemotherapy. The clinical curative effect and adverse reaction in two groups were evaluated. Results After treatment, the total effective rate of control group was 24.0%, and the clinical benefit rate was 52.0%, while the total effective rate of treatment group was 44.0%, and the clinical benefit rate was 74.0%, and there were differences between two groups(P < 0.05). Adverse reactions such as reducing of white blood cells, red blood cells, and neutropenia, nausea, vomiting, diarrhea, fever, inflammation of oral mucosa can happen in two groups during the course of the treatment, and the incidence rate of treatment group was significantly lower than that of the control group, and there were differences between two groups(P < 0.05). The progression-free survival(PFS) and overall survival(OS) in treatment group were 5.2 months and 10.3 months, respectively, while those in the control group were 3.8 months and 9.7 months, and there were differences between two groups(P < 0.05). Conclusion Pemetrexed combined with cisplatin has the good clinical effect in treatment of cervical cancer, and can reduce the adverse reaction of chemotherapy, which is worth clinical promotion.
Related Articles
No related articles found